Neoadjuvant Talazoparib Shows Activity in BRCA1/2+ Early HER2-Negative Breast Cancer
August 30th 2021
Jennifer K. Litton, MD, discusses the rationale for examining neoadjuvant talazoparib in patients with BRCA1/2-positive, early HER2-negative breast cancer, safety and efficacy results from NEOTALA, and next steps for research.